SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

ROCTAVIAN

BMRN·BIOMARIN PHARMACEUTICAL INC
BEARISH
Drug Impact Rating1/10
Trial phase
Approved (FDA June 2023, EMA August 2022), then voluntarily withdrawn February 2026.
Time to market
Withdrawn from market as of February 2026; no longer commercially available.
Why 1/10
ROCTAVIAN was voluntarily withdrawn from the market on February 23, 2026, and there are no scheduled regulatory or pivotal-readout catalysts for this drug going forward. It is a withdrawn, discontinued asset with no remaining commercial or clinical binary events.
Actionable Insight BEARISH

ROCTAVIAN is a withdrawn drug with no remaining commercial presence or regulatory catalysts. BioMarin's stock thesis now rests entirely on VOXZOGO (achondroplasia), its enzyme replacement therapy portfolio, and the recently acquired Alesta Therapeutics pipeline. The Q3 2026 earnings beat (EPS $0.23 vs -$0.08 consensus) shows the company is moving past the ROCTAVIAN failure, but the drug itself is a closed chapter for investors.

Price Chart

Loading chart...

Executive Summary

ROCTAVIAN (valoctocogene roxaparvovec) is a one-time gene therapy for severe hemophilia A developed by BioMarin Pharmaceutical (BMRN). It won FDA approval on June 29, 2023, as the first gene therapy for this indication, but was a commercial failure due to its $2.9 million price tag, complex reimbursement logistics, and slow physician/patient adoption. After failing to find a buyer, BioMarin voluntarily withdrew ROCTAVIAN from the market on February 23, 2026, taking roughly $240 million in charges. The drug was available through May 2026 in the US, Germany, and Italy before being fully discontinued. As of November 2026, ROCTAVIAN is a withdrawn asset with no remaining catalysts for investors.

How It Works

ROCTAVIAN is a one-time gene therapy that uses a harmless, modified virus (AAV serotype 5) to deliver a working copy of the gene for factor VIII, a blood-clotting protein that people with severe hemophilia A lack. A single intravenous infusion is designed to enable the patient's own liver cells to produce factor VIII long-term, reducing or eliminating the need for regular factor VIII infusions.

Trial Status

ROCTAVIAN completed Phase 3 (GENEr8-1, NCT03370913) and Phase 1/2 trials demonstrating durable hemostatic efficacy and factor VIII activity for 5+ years. Final 5-year Phase 3 results were published in 2026 confirming no new safety signals. Despite positive clinical data, commercial uptake was negligible due to pricing and reimbursement barriers.

The Two-Sided Case

▲ Bull Case4
ROCTAVIAN was the first FDA-approved gene therapy for severe hemophilia A (June 29, 2023), a genuine scientific milestone that demonstrated durable hemostatic efficacy for 5+ years in Phase 3 GENEr8-1 trial data.
The withdrawal was voluntary and driven by commercial/reimbursement dynamics, not safety or efficacy concerns. The drug's clinical profile remained intact.
Removing ROCTAVIAN simplifies BioMarin's portfolio and removes a cash-burning commercial operation, allowing management to focus on higher-growth assets like VOXZOGO.
BioMarin's Q3 2026 earnings (reported Nov 2, 2026) showed revenue of $1.02B (+32% YoY) and EPS of $0.23 beating consensus by $0.31, demonstrating the company's resilience post-withdrawal.
▼ Bear Case4
ROCTAVIAN was a high-profile commercial failure: priced at $2.9 million per dose, it faced severe reimbursement hurdles and negligible uptake despite FDA approval.
BioMarin took roughly $240 million in charges (including a $119 million inventory write-off) in Q4 2025 related to the withdrawal, a direct hit to shareholders.
The drug's failure raises questions about the viability of one-time gene therapy business models, which may weigh on BioMarin's gene therapy pipeline efforts.
BioMarin was unable to find any qualified buyer for ROCTAVIAN despite a months-long search, underscoring the asset's perceived lack of value.

Upcoming Catalysts

  • None. ROCTAVIAN has been withdrawn from the market and is no longer in development or commercialization.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 7

Hover a chip for the title
1 biomarin.com2 fda.gov3 biomarin.com4 fiercepharma.com5 bleeding.org6 prnewswire.com7 drugs.com